New, highly potent and non-toxic, chromone inhibitors of the human breast cancer resistance protein ABCG2
- 1 October 2016
- journal article
- research article
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 122, 291-301
Abstract
No abstract availableKeywords
Funding Information
- ANR Labex Arcane (ANR-11-LABX-0003-01)
- Ligue Nationale Contre le Cancer (Equipe Labellisée 2014)
- CNPq (201403/2014-5)
This publication has 23 references indexed in Scilit:
- The Inhibitor Ko143 Is Not Specific for ABCG2The Journal of Pharmacology and Experimental Therapeutics, 2015
- Targeting the Multidrug ABCG2 Transporter with Flavonoidic Inhibitors: In Vitro Optimization and In Vivo ValidationCurrent Medicinal Chemistry, 2011
- The multidrug resistance half-transporter ABCG2 is purified as a tetramer upon selective extraction from membranesBiochimica et Biophysica Acta (BBA) - Biomembranes, 2010
- Inhibitors of cancer cell multidrug resistance mediated by breast cancer resistance protein (BCRP/ABCG2)Anti-Cancer Drugs, 2006
- Characterization of Oligomeric Human Half-ABC Transporter ATP-binding Cassette G2Journal of Biological Chemistry, 2004
- Functional Characterization of the Human Multidrug Transporter, ABCG2, Expressed in Insect CellsBiochemical and Biophysical Research Communications, 2001
- Inhibition of BCRP-mediated drug efflux by fumitremorgin-type indolyl diketopiperazinesBioorganic & Medicinal Chemistry Letters, 2001
- A multidrug resistance transporter from human MCF-7 breast cancer cellsProceedings of the National Academy of Sciences, 1998
- Overexpression of a Transporter Gene in a Multidrug-Resistant Human Lung Cancer Cell LineScience, 1992
- THE BIOCHEMISTRY OF P-GLYCOPROTEIN-MEDIATED MULTIDRUG RESISTANCEAnnual Review of Biochemistry, 1989